Interview with Cesar Rengifo, President, GSK Brazil
You’ve made some bold moves in your career – from the head of vaccines in Latin America, followed by stints in Colombia, Puerto Rico, and finally Brazil. What brought you…
Address: Praça São Marcos, 624 05455-050 – São Paulo – SP,Brazil
Tel: 0800-772-4656
Web: http://www.ferring.com.br/
In 1950 in Malmö, Sweden, Dr. Frederik Paulsen founded Laboratoriet Nordiska hormone, which in 1954 changed its name to Ferring.
A world leader in peptide hormones, Ferring was a pioneer in developing and selling pharmaceutical products based on natural hormones, the pituitary-produced peptide. Dr. Paulsen was convinced that these new compounds could be used to supplement deficiencies and abnormalities, making an invaluable role in the treatment of various diseases.
Five decades later, Dr. Paulsen’s predictions have proven inaccurate. Today, the peptides are widely used in various treatments of Ferring.
Over the past years Ferring has expanded its activities beyond its European base and now have subsidiaries operating in over 40 countries, including Brazil, which is the company’s fastest-growing subsidiary. Its annual turnover is 700 million and has over 3,000 employees. Over the next three to five years, the group aims to triple sales in Brazil.
Propess, BioGaia, DDAVP, Choragon, Bravelle, FemLab, Menogon
You’ve made some bold moves in your career – from the head of vaccines in Latin America, followed by stints in Colombia, Puerto Rico, and finally Brazil. What brought you…
We asked Mr. Santos regarding his recommendations to help the government innovate, compete, and grow in the pharmaceutical industry here in Brazil on the Human Genetic Therapies side. Is there…
Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that…
PGS is a member of ABRACRO, but is in a unique position as both a CRO and a service provider to CROs and pharmaceutical companies. Can you elaborate on the…
Sao Paulo state is responsible for some 85% of pharmaceutical production, and last week Minister Pimentel was in the city of Sao Paulo elaborating on his BrazilMaior plan with strategic…
Besins finally arrived in Brazil in 2010. In addition to introducing the company to the market, would you also elaborate on the strategic motivation behind this decision? Besins Healthcare is…
Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free…
Two days ago, the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan…
Your position unites two somewhat incongruous titles – Director of Sustainability, and New Business. How did this come to be, and what if any overlap is there between these two…
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
What have been some of the recent milestones and achievements contributing to AstraZeneca Brazil’s status as the country’s fastest growing MNC? What happened in the last 10 years was a…
An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of hypertensives having their condition…
See our Cookie Privacy Policy Here
